Company Performance - Amgen's stock closed at $294.76, reflecting a -1.17% change from the previous day, underperforming the S&P 500's daily loss of 0.01% [1] - Over the last month, Amgen's shares increased by 2.98%, outperforming the Medical sector's loss of 1.59% but lagging behind the S&P 500's gain of 5.37% [1] Upcoming Earnings Report - Amgen is set to release its earnings on August 5, 2025, with an expected EPS of $5.22, representing a 5.03% increase from the prior-year quarter [2] - The Zacks Consensus Estimate for revenue is projected at $8.86 billion, up 5.64% from the year-ago period [2] Annual Estimates - For the annual period, the Zacks Consensus Estimates predict earnings of $20.84 per share and revenue of $35.23 billion, indicating increases of +5.04% and +5.41% respectively from the last year [3] - Recent analyst estimate revisions suggest a positive outlook for Amgen's business operations and profit generation capabilities [3] Valuation Metrics - Amgen is currently trading at a Forward P/E ratio of 14.31, which is below the industry average Forward P/E of 18.7, indicating a discount relative to its peers [6] - The company has a PEG ratio of 2.7, compared to the industry average PEG ratio of 1.48, suggesting that Amgen's anticipated earnings growth is factored into its valuation [7] Industry Ranking - The Medical - Biomedical and Genetics industry, which includes Amgen, has a Zacks Industry Rank of 82, placing it in the top 34% of over 250 industries [8] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [8]

Core Insights - The article introduces "The Undercovered Dozen," highlighting twelve actionable investment ideas on tickers with less coverage, which can include both large caps and small caps [1] Group 1: Inclusion Criteria - Tickers must have a market cap greater than $100 million [1] - Tickers must have received more than 800 symbol page views in the last 90 days on Seeking Alpha [1] - Tickers must have fewer than two articles published in the past 30 days [1] Group 2: Purpose and Follow-up - The initiative aims to provide investors with a weekly review of undercovered investment ideas from analysts [1]

Core Insights - Amgen is positioned to continue its earnings-beat streak, having a history of exceeding earnings estimates, particularly in the last two quarters with an average surprise of 11.68% [1][5] Earnings Performance - In the last reported quarter, Amgen achieved earnings of $4.9 per share, surpassing the Zacks Consensus Estimate of $4.16 per share by 17.79% [2] - In the previous quarter, Amgen's earnings were $5.31 per share against an expected $5.03 per share, resulting in a surprise of 5.57% [2] Earnings Estimates and Predictions - There has been a favorable change in earnings estimates for Amgen, with a positive Earnings ESP of +0.07%, indicating bullish sentiment among analysts regarding its near-term earnings potential [5][8] - The combination of a positive Earnings ESP and a Zacks Rank of 3 (Hold) suggests a high likelihood of another earnings beat, with historical data showing that such combinations lead to positive surprises nearly 70% of the time [6][8] Earnings ESP Explanation - The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate, with the Most Accurate Estimate reflecting the latest analyst revisions, which may be more accurate [7] - A negative Earnings ESP can reduce predictive power but does not necessarily indicate an earnings miss [9] Importance of Earnings ESP - Many companies beat consensus EPS estimates, but this is not the sole reason for share price gains; stability can also occur even with missed estimates [10]

Group 1 - The National Medical Products Administration (NMPA) has accepted the marketing application for Baiyue Shenzhou's Talatuzumab injection, which is intended for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) who have failed at least second-line treatment [1] - Talatuzumab is a first-in-class DLL3/CD3 bispecific antibody that may bring breakthrough advancements in the treatment of SCLC, a type of lung cancer with a high rate of incidence and mortality [1][2] - SCLC accounts for approximately 15% of all lung cancer cases, with about 70% of patients diagnosed at the extensive stage, leading to a median overall survival (mOS) of only 4 to 5 months after initial treatment [1] Group 2 - DLL3 protein is considered a highly attractive therapeutic target in SCLC, with up to 96% of SCLC patients expressing this protein [2] - Talatuzumab utilizes an innovative T-cell engaging (BiTE) structure, which allows for effective targeting of tumor cells and T-cells, potentially making it a novel therapy for SCLC [2] - Interim analysis from a global Phase 3 clinical trial presented at the 2025 American Society of Clinical Oncology annual meeting showed that Talatuzumab treatment resulted in a median overall survival of 13.6 months, significantly extending survival by 5.3 months compared to standard chemotherapy [2]

Core Insights - Amgen Inc is a leading biopharmaceutical company focused on research and development of medicines for various diseases, including inflammation, rare diseases, and cardiovascular diseases [1] Company Overview - Amgen operates globally, emphasizing its commitment to developing innovative therapies [1] Investment Perspective - The company aims to provide long-term returns for investors through its focus on fundamental analysis of dividend and growth equities across diverse sectors [1]

Core Viewpoint - Amgen (AMGN) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook based on rising earnings estimates, which significantly influence stock prices [1][2]. Earnings Estimates and Stock Price Impact - The Zacks rating system emphasizes the importance of changing earnings estimates, which are strongly correlated with near-term stock price movements [3][5]. - Institutional investors often rely on earnings estimates to determine a company's fair value, leading to significant stock price movements based on these estimates [3]. Amgen's Earnings Outlook - For the fiscal year ending December 2025, Amgen is expected to earn $20.85 per share, which remains unchanged from the previous year [7]. - Over the past three months, the Zacks Consensus Estimate for Amgen has increased by 1.2%, reflecting a positive trend in earnings estimates [7]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have generated an average annual return of +25% since 1988 [6]. - The upgrade of Amgen to a Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [9].

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Amgen (AMGN) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Amgen is one of 986 individual stocks in the Medical sector. Collectively, these companies sit at #8 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. Th ...

Company Overview - Amgen is one of the largest biotech companies globally, with a strong presence in oncology/hematology, cardiovascular disease, inflammation, bone health, and rare diseases markets [11] - The company has developed successful drugs such as Epogen and Neupogen, and launched next-generation products like Aranesp and Neulasta [11] - Amgen's acquisition of Immunex Corporation provided access to the blockbuster drug Enbrel, although older drugs are facing declining sales due to competition [11] Financial Performance - Amgen has a Zacks Rank of 3 (Hold) and a VGM Score of A, indicating a solid position in the market [12] - The company is forecasted to achieve year-over-year earnings growth of 5.1% for the current fiscal year [12] - Recent upward revisions in earnings estimates by five analysts for fiscal 2025 have increased the Zacks Consensus Estimate by $0.09 to $20.85 per share [12] - Amgen has an average earnings surprise of +8.3%, reflecting its ability to exceed earnings expectations [12] Investment Potential - With a solid Zacks Rank and top-tier Growth and VGM Style Scores, Amgen is recommended for investors looking for growth opportunities [13]

Core Insights - The article emphasizes the importance of quantitative research, financial modeling, and risk management in equity valuation and market trends [1] - It highlights the experience of the analyst in leading teams for model validation and stress testing, showcasing a strong background in both fundamental and technical analysis [1] - The collaboration between the analyst and their research partner aims to provide high-quality, data-driven insights for investors [1] Company and Industry Analysis - The focus is on uncovering high-growth investment opportunities through rigorous risk management and a long-term perspective on value creation [1] - There is a particular interest in macroeconomic trends, corporate earnings, and financial statement analysis, which are crucial for providing actionable investment ideas [1]

Stock Recommendations - Freeport-McMoRan (FCX) is breaking above resistance at $43 to $45, a level it has struggled with since 2021 [1] - Honeywell's breakup value is expected to unlock shareholder value [1] - Caterpillar's increased customer engagement is projected to increase sales [1] - An unnamed stock is showing a series of higher lows and breaking out above the 200-day moving average [1]